Bob Li
MD, PhD, MPH
Attending Physician and Associate Professor
👥Biography 个人简介
Bob Li led DESTINY-Lung01 and DESTINY-Lung02 establishing trastuzumab deruxtecan (T-DXd) as the first approved targeted therapy for HER2-mutant NSCLC. His work defined HER2 exon 20 insertions as actionable alterations and transformed outcomes for this patient population. He continues to study HER2 ctDNA monitoring and resistance mechanisms.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Bob Li 的研究动态
Follow Bob Li's research updates
留下邮箱，当我们发布与 Bob Li（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment